Latest action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 443.
Bill is filed in its originating chamber and assigned a number.
Sponsor
John Reed (D-RI)
Filed in the Senate.
Next: In Committee
Members of the committee(s) the bill was referred to
Bill reauthorizes federal funding and oversight for stem cell research and therapeutic development.
The problem
Previous stem cell research authorization expired. Scientists need clear federal funding rules and legal framework to continue medical research using stem cells.
The proposal
Bill extends federal authority to fund stem cell research, sets new research guidelines, and establishes regulatory framework for developing stem cell-based treatments.
The impact
Research institutions, scientists, patients with diseases like Parkinson's and diabetes, and biotech companies gain continued federal support and legal clarity for stem cell work.
Stem cell research may lead to new treatments for Parkinson's, diabetes, spinal injuries, and other diseases. Federal funding helps scientists move research faster toward helping sick people.
Biotech companies and research institutions create jobs in medicine and science. Federal support attracts private investment in the stem cell industry.
Clear federal rules let researchers and companies plan long-term projects without legal confusion. This stability attracts talent and investment to the field.
US researchers stay competitive globally when federal funding continues. Other countries invest heavily in stem cell research.
Some people believe certain stem cell research methods raise moral questions about embryos or human dignity. Religious and conservative groups oppose some types of research.
Federal funding comes from tax dollars. Some argue money should go elsewhere or that private companies should pay for research benefits they profit from.
Research investment doesn't guarantee successful treatments. Funding stem cell work may not deliver promised medical breakthroughs for years or decades.
New federal rules could create paperwork and compliance costs for research institutions, potentially slowing scientific progress.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.